Floaters

Floaters, known medically as myodesopsia or vitreous opacities, are moving shapes that appear in the field of vision. They may look like spots, dots, threads, cobwebs, rings, or floating clouds, and they tend to drift when the eye moves and then slowly settle when the eye stops. They are most visible against bright, uniform backgrounds such as a blue sky, a white wall, or a computer screen. Floaters are caused by particles or condensations within the vitreous—the gel-like substance that fills the large chamber inside the eye between the lens and the retina. When these particles cast shadows on the retina (the light-sensitive tissue at the back of the eye), the brain perceives them as floating shapes.

The vitreous is made up of approximately 99% water, held in a stable gel structure by a scaffolding of collagen fibrils and a molecule called hyaluronic acid. This structure is remarkably clear in youth but degenerates with age—collagen fibers clump together, the gel liquefies in patches, and the resulting opacities float through the vitreous cavity and produce floaters. Floaters fall under the broader category of vitreous diseases—a group of conditions affecting the vitreous chamber of the eye that ranges from entirely benign age-related changes to potentially sight-threatening emergencies such as retinal tears and retinal detachment.

Floaters are extremely common. A large survey study found that approximately 76% of the general population reports seeing them at some point, and about one-third of people with floaters describe their vision as meaningfully impaired by them. Most floaters are benign and self-resolving, or at least stable—the brain adapts and stops attending to them over time. However, a sudden onset of new floaters—particularly accompanied by flashing lights, a visual field defect, or a darkened area of vision—can signal a serious event such as a retinal tear or retinal detachment and requires urgent ophthalmological evaluation the same day.

Ophthalmologists classify floaters by their underlying cause and composition. Each type has a distinct appearance, time course, and level of clinical urgency.

• Degenerative vitreous floaters (vitreous syneresis): the most common type in the general population. As the vitreous ages, its collagen fibers clump together into light-scattering aggregates while the surrounding gel liquefies. This produces the classic slowly drifting spots, strands, and cobwebs that most people notice beginning in their thirties or forties. Onset is gradual.
• Posterior vitreous detachment (PVD)-associated floaters: the most common cause of sudden new floaters in adults over 50. As vitreous liquefaction progresses, the entire gel separates from the back surface of the retina. The attachment point around the optic nerve creates a ring-shaped floater called the Weiss ring—the hallmark of complete PVD. The separation can generate traction on the retina that is felt as flashes of light. In about 14% of acute PVD cases, this traction causes a full-thickness retinal tear, making same-day evaluation essential.
• Vitreous hemorrhage: Blood entering the vitreous cavity from ruptured vessels produces floaters ranging from a shower of small dark dots to a dense, reddish-brown cloud that can dramatically reduce vision. The leading cause is proliferative diabetic retinopathy—the most serious eye complication of diabetes—in which abnormal new blood vessels bleed into the vitreous. Other causes include retinal tears, trauma, and retinal vein occlusion. A vitreous hemorrhage dramatically raises the likelihood that a retinal tear is present and requires urgent evaluation.
• Inflammatory floaters (vitritis): When the blood-ocular barrier breaks down in conditions such as uveitis (inflammation inside the eye), sarcoidosis, toxoplasmosis, or infection, white blood cells and protein aggregates enter the vitreous, producing clumps, haze, or a specific pattern called vitreous snowballs. Tobacco dust (also called Shafer’s sign)—brownish-black pigment cells visible in the vitreous on slit-lamp examination—is a critical emergency sign indicating a retinal tear and requires same-day evaluation regardless of other symptoms.
• Asteroid hyalosis: a benign degenerative condition in which calcium-phospholipid spheres accumulate within the vitreous gel, suspended in the collagen framework. The appearance through the ophthalmoscope is dramatic—like a snow globe full of glittering spheres—but most patients are entirely asymptomatic despite the impressive finding. It affects approximately 0.5–1.9% of ophthalmology patients and is most often unilateral.
• Synchysis scintillans (cholesterosis bulbi): a rare condition in severely damaged eyes in which cholesterol crystals derived from the breakdown of old intraocular hemorrhage accumulate in the vitreous cavity. The crystals shimmer with gold and silver colors and settle to the bottom of the eye when it is still, then scatter like a snow globe with movement. Unlike asteroid hyalosis, the crystals are mobile and gravity-dependent.
• Congenital vitreous opacities: Persistent fetal vasculature (PFV) and persistent hyaloid artery remnants are present from birth and represent normal embryological structures that failed to regress. A Mittendorf dot—a small white spot on the back surface of the lens—is a common benign remnant. Significant persistent fetal vasculature can impair vision and may require treatment in infancy.
• Vision-degrading myodesopsia (VDM): not a separate type by cause, but a recognized clinical severity category. VDM describes floaters that have crossed the threshold of measurably reduced contrast sensitivity and meaningful quality-of-life impairment, documented by validated testing instruments. This subset represents the patients for whom active treatment—rather than observation alone—may be appropriate.

Floaters arise through two fundamental pathways: changes within the vitreous gel itself due to normal aging, and introduction of abnormal material—blood, inflammatory cells, or crystals—into the vitreous from a disease process elsewhere in the eye. The specific cause determines the urgency of evaluation and the management approach.

The most common cause is age-related degeneration of the vitreous’s internal structure. The normal vitreous depends on an even distribution of hyaluronic acid molecules, keeping the collagen fiber scaffolding evenly spaced and transparent. With age, hyaluronic acid concentration falls, the collagen fibers lose their separation and clump together into light-scattering aggregates, and the gel begins to liquefy in patches—a process called vitreous syneresis. As liquefaction progresses, the entire vitreous pulls away from the back of the eye (posterior vitreous detachment). Nearsightedness (myopia) is a powerful accelerant of this process: the longer axial length of a myopic eye increases vitreous volume and stresses the vitreous structure, causing syneresis and PVD to occur 10 to 15 years earlier than in non-myopic eyes. People with moderate-to-severe myopia are 3.5 times more likely to have bothersome floaters than those with normal vision, and genetic studies have confirmed a direct causal relationship between myopia and vitreous disorders. Other contributing causes include:

• Diabetes mellitus: This can lead to proliferative diabetic retinopathy, in which the retina responds to reduced blood flow by growing fragile new blood vessels that break easily and bleed into the vitreous.
• Uveitis and intraocular inflammation: The breakdown of the blood-ocular barrier in inflammatory eye disease allows immune cells and proteins to enter the vitreous, producing inflammatory opacities.
• Trauma: A blow to the eye can tear retinal vessels, cause retinal breaks, and introduce blood or pigment cells into the vitreous.
• Prior intraocular surgery: Cataract surgery can accelerate the onset of posterior vitreous detachment; previous vitreoretinal surgery alters vitreous structure.
• Crystal deposition: Calcium-phospholipid complexes in asteroid hyalosis, and cholesterol crystals from chronic blood breakdown in synchysis scintillans, produce characteristic floaters through non-inflammatory deposition processes.

The following factors are associated with a higher likelihood of developing significant floaters or of having floaters that signal a serious underlying condition.

• Older age: the most important risk factor. Posterior vitreous detachment is present in 24% of adults aged 50 to 59 and in 87% of adults over age 80. Vitreous liquefaction begins as early as the third decade of life.
• Myopia (nearsightedness): People with myopia have a 3.5-fold higher risk of moderate-to-severe floaters compared to those with normal vision. High myopia (greater than -6 diopters) causes PVD to occur a decade or more earlier than in non-myopic eyes.
• Hyperopia (farsightedness): This is also associated with a higher rate of moderate-to-severe floaters (approximately 4.4 times the risk of emmetropes), though the mechanism is less well established.
• Diabetes mellitus: This increases risk both through direct acceleration of vitreous degeneration and through the risk of proliferative diabetic retinopathy and vitreous hemorrhage.
• History of intraocular surgery: Cataract surgery significantly accelerates PVD onset. Previous vitreoretinal surgery increases the risk of recurrent vitreous opacities.
• Intraocular inflammation (uveitis): Active and chronic uveitis promotes both inflammatory floaters and accelerated vitreous degeneration.
• Ocular trauma: This increases the risk of vitreous hemorrhage, retinal tears, and acute onset of floaters.
• Prior retinal detachment or retinal tear: A history of retinal disease in one eye significantly elevates the risk of subsequent problems in both eyes.

There is no population-wide screening program for floaters. The great majority of people with benign floaters from age-related vitreous degeneration do not require any formal screening beyond their regular comprehensive eye examinations. However, certain symptoms — when they develop suddenly — are red flags that require same-day emergency ophthalmological evaluation, because they may indicate a retinal tear or retinal detachment that can cause permanent vision loss if not treated within hours.

The following symptoms require same-day urgent evaluation — do not wait for a scheduled appointment:

• A sudden shower of many new floaters: particularly a significant increase in number in a previously stable eye.
• Flashing lights (photopsia) alongside new floaters: caused by the retina being pulled by the separating vitreous, indicates active traction.
• A Curtain, Shadow, or Dark Area in the Peripheral or Central Field of Vision: may indicate retinal detachment until proven otherwise.
• Subjective visual reduction, blurring, or the appearance of a reddish or dark haze:  consistent with vitreous hemorrhage, which substantially raises the likelihood that a retinal tear is present.

For patients already known to have an uncomplicated posterior vitreous detachment (confirmed on dilated examination with no retinal tear found), a follow-up dilated examination at approximately six weeks is recommended, because about 3 to 4 percent of such patients will develop a new retinal tear at the follow-up visit even when none was present initially. Annual dilated eye examinations are recommended for all adults, and more frequently for people with high myopia, diabetes, prior retinal disease, or a history of retinal detachment. Floaters from age-related vitreous changes cannot be prevented. Modifiable risk reduction focuses on keeping diabetes well controlled to reduce the risk of proliferative retinopathy and vitreous hemorrhage, wearing protective eyewear to prevent traumatic eye injuries, and treating uveitis promptly to limit inflammatory vitreous opacification.

The defining experience of floaters is the perception of translucent or opaque moving shapes in the field of vision—typically most visible against a bright background such as a blue sky, white wall, or lit computer screen. The shapes move with eye movement and then drift slowly when the eye stops, due to the inertia of the vitreous gel. This characteristic lag—moving with the eye but continuing to drift after the eye stops—distinguishes floaters from other visual phenomena.

Common floater appearances and their associated causes include:

• Spots or dots: multiple small, dark specks; the most common presentation of vitreous syneresis
• Cobwebs, threads, or worm-like strands: condensed collagen fibrils from age-related vitreous degeneration
• A large ring or horseshoe shape: the Weiss ring, a characteristic finding of complete posterior vitreous detachment
• A cloud, veil, or shower of dark particles: vitreous hemorrhage; particularly when accompanied by a reddish or brownish tint
• Glittering gold and silver crystals that settle when the eye is still: synchysis scintillans, caused by cholesterol crystal deposits
• A snow-globe-like field of suspended spheres: asteroid hyalosis; typically more dramatic on examination than in the patient’s perception
• Flashes of light (photopsia): not floaters themselves but frequently accompanying symptoms during active posterior vitreous detachment, caused by mechanical stimulation of the retina from vitreous traction

Beyond the physical appearance of floaters, their psychological and functional impact is often underestimated. Research using quality-of-life utility measures has found that chronic, bothersome floaters have a quality-of-life burden comparable to mild-to-moderate angina (chest pain from heart disease). About 94% of patients who seek surgical treatment for floaters report moderate-to-severe quality-of-life impairment before treatment, including anxiety, hypervigilance about their visual symptoms, difficulty with driving, reading, and screen-based work, and, in some cases, clinical depression. The key measurable functional marker of severe floaters is reduced contrast sensitivity—the ability to distinguish objects from their background—which can be objectively documented with standardized testing.

• In young adults in their 20s and 30s: Floaters are common and are almost always benign vitreous syneresis, particularly in myopic individuals. Urgent evaluation is rarely needed unless onset is sudden or associated with flashes or a visual field defect.
• In adults aged 50 to 65: This is the peak period of posterior vitreous detachment onset. Any sudden new shower of floaters, particularly with flashing lights, must be evaluated the same day by an ophthalmologist with a dilated fundus examination. The risk of an associated retinal tear is approximately 14–15%.
• In adults over 65: Most people in this age group have already completed their PVD. New or significantly worsening floaters should prompt evaluation for secondary causes such as vitreous hemorrhage from diabetic retinopathy or retinal vein occlusion. Tobacco dust (Shafer’s sign) detected on examination at any age is an ophthalmological emergency indicating a likely retinal break.

Floaters are evaluated by an ophthalmologist or optometrist. The primary goal at the initial evaluation is not simply to confirm that floaters are present—the patient already knows that—but to determine whether the floaters are benign and require only observation, or whether they signal a retinal tear, retinal detachment, hemorrhage, or other serious condition requiring urgent intervention. A comprehensive dilated eye examination is the essential diagnostic tool for anyone presenting with new floaters.

• Dilated fundus examination with binocular indirect ophthalmoscopy (BIO) and scleral depression: the gold standard for evaluating new floaters. Dilating drops widen the pupil, and the doctor examines the entire retina, including the far peripheral retina, using a wide-angle lens and a bright light source while pressing on the outside of the eye (scleral depression) to view the retina’s extreme edges. Direct ophthalmoscopy alone—with an undilated pupil—is insufficient for this examination and should not be used as the sole assessment for acute-onset floaters.
• Slit-lamp biomicroscopy: a magnified examination of the vitreous and anterior eye that can detect Shafer’s sign (tobacco dust—brownish pigment cells floating in the vitreous that carry a very high likelihood of an associated retinal break), vitreous hemorrhage, inflammatory cells, and the Weiss ring. Detecting Shafer’s sign on slit-lamp examination has a likelihood ratio of 44 for an associated retinal tear.
• B-scan ultrasonography: a sound-wave imaging technique that produces cross-sectional images of the interior of the eye. It is used when vitreous hemorrhage or other media opacity prevents direct visualization of the retina. B-scan can detect PVD, retinal detachment, vitreous masses, and certain types of floater deposits, such as asteroid hyalosis, with high sensitivity even when the retina cannot be seen directly.
• Fundus photography: Color and wide-field retinal photographs document the vitreous appearance, posterior vitreous detachment status, and any retinal findings for comparison at future visits. They provide an objective baseline against which subsequent changes can be measured.
• Optical coherence tomography (OCT): High-resolution cross-sectional imaging of the retina and vitreous interface detects vitreomacular traction (abnormal attachment of the vitreous to the central macula), epiretinal membrane formation, and retinal edema that may accompany floaters. OCT is particularly useful for evaluating whether floaters are associated with any structural threat to central vision.
• Straylight measurement (C-Quant): a quantitative test of the light-scattering effect of vitreous opacities on vision. It objectively documents contrast sensitivity reduction and is used to classify a patient as meeting the threshold for vision-degrading myodesopsia when the decision about active treatment is being made.

The appropriate treatment for floaters depends entirely on their cause, severity, and impact on daily function. The vast majority of floaters from benign age-related vitreous degeneration require no treatment—the brain typically adapts to their presence over weeks to months and stops attending to them. For many patients, reassurance that the floaters are benign, an explanation of what they are, and confirmation that no retinal tear is present is all that is needed. However, for a significant minority whose floaters persistently degrade quality of life and measurably impair vision, treatment options are available and effective.

Observation is always the first approach for newly discovered benign floaters in the absence of retinal complications. In the weeks following a posterior vitreous detachment, floaters often settle inferiorly away from the central visual axis, become less prominent as the brain adapts, and cause progressively less bother. Many patients whose floaters initially felt intolerable report being largely unaware of them within three to six months. If symptoms do persist and are significantly impacting quality of life, the clinical conversation shifts toward active treatment. For patients whose floaters are causing documented contrast sensitivity reduction and meeting the threshold for vision-degrading myodesopsia, two treatment options are available: yttrium aluminium garnet (YAG) laser vitreolysis and pars plana vitrectomy.

YAG laser vitreolysis is a nonsurgical in-office procedure in which a neodymium-YAG (Nd:YAG) laser is used to vaporize or fragment discrete vitreous floater opacities into smaller particles that no longer cast significant shadows on the retina. It is most effective for well-defined, discrete floaters—particularly the Weiss ring from a completed posterior vitreous detachment, which often responds dramatically to a single treatment session. It is less effective for small, diffuse, or posteriorly located floaters. The procedure requires the floater to be accessible and clearly visible under slit-lamp examination. Risks include the rare induction of elevated intraocular pressure, cataract from laser contact with the lens, and retinal damage if the laser is aimed too posteriorly. In appropriate candidates with Weiss ring floaters, published outcomes show good symptomatic improvement. Pars plana vitrectomy (PPV) is the definitive surgical treatment for severe, vision-degrading floaters. In this procedure, performed in an operating room under local or general anesthesia, the vitreoretinal surgeon inserts fine instruments through tiny incisions in the white part of the eye (sclera), removes all or most of the vitreous gel along with its opacities, and replaces it with saline solution. PPV provides a near-complete cure for floaters, with published studies showing 94–97% patient satisfaction and significant objective improvement in contrast sensitivity and straylight measurements. The main risks of PPV include accelerated cataract formation (most common, affecting most phakic—natural lens intact—patients within two to three years), retinal tear or detachment (estimated 1–2%), and infection (endophthalmitis, very rare). PPV is generally reserved for patients whose floaters meet objective criteria for vision-degrading myodesopsia and who have not responded adequately to conservative management or to YAG laser vitreolysis.

For most people, floaters are a nuisance that becomes less noticeable over time as the brain learns to filter them out. Understanding what floaters are—harmless shadows from the aging vitreous—removes much of the anxiety that commonly accompanies the initial discovery of new floaters. The vast majority of people with floaters live entirely normal visual lives without any medical intervention. The most important action anyone with floaters can take is to know the warning signs that require same-day urgent care—a sudden increase in floater number, new flashing lights, a curtain in the visual field, or reddish-brown haze—and to act on them immediately if they occur. Regular dilated eye examinations, particularly for adults over 50, for people with myopia, and for those with diabetes, are the most reliable way to ensure that any serious complications are caught early. For the smaller group of patients whose floaters persistently degrade their quality of life and vision, effective treatment options exist and have a high rate of patient satisfaction. You do not have to simply tolerate floaters that are meaningfully affecting your daily activities—speak to your ophthalmologist about whether evaluation for treatment is appropriate for your situation.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of floaters and related vitreous disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.